{"id":"NCT05399459","sponsor":"Pfizer","briefTitle":"Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)","officialTitle":"Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-08-09","primaryCompletion":"2024-01-19","completion":"2024-01-19","firstPosted":"2022-06-01","resultsPosted":"2025-02-10","lastUpdate":"2025-03-07"},"enrollment":897,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"Rimegepant 25 MG","otherNames":["BHV3000"]},{"type":"DRUG","name":"Rimegepant 75 MG","otherNames":["BHV3000"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Rimegepant 25 mg","type":"EXPERIMENTAL"},{"label":"Rimegepant 75 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to determine the appropriate dose of rimegepant in Japanese subjects, as well as to evaluate the efficacy, safety, and tolerability of rimegepant in Japanese subjects for the acute treatment of migraine.","primaryOutcome":{"measure":"Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose","timeFrame":"2 hours post-dose","effectByArm":[{"arm":"Rimegepant 25 mg","deltaMin":21,"sd":null},{"arm":"Rimegepant 75 mg","deltaMin":32.4,"sd":null},{"arm":"Placebo","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":50,"countries":["Japan"]},"refs":{"pmids":["40586377"],"seeAlso":["https://pmiform.com/clinical-trial-info-request?StudyID=BHV3000-313"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":239},"commonTop":["Nasopharyngitis"]}}